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Chronic tubulointerstitial changes induced by germanium dioxide in
comparison with carboxyethylgermanium sesquioxide. Chronic nephro-
toxicity was investigated in rats orally administered germanium dioxide
(Ge02) and carboxyethylgermanium sesquioxide (Ge-132) for 24 weeks.
Increased BUN and serum phosphate as well as decreased creatinine
clearance, weight loss, anemia and liver dysfunction were apparent at
week 24 only in the Ge02 treated group. Vacuolar degeneration and
granular depositions were observed by light microscope in the degen-
erated renal distal tubules in the rats of this group, with the semiquan-
titative scores of tubular degeneration being 95 9% in the Ge02
group, 3 1% in the Ge-l32 group and 1 1% in the control group,
respectively. Electron microscopy revealed electron-dense inclusions
in the swollen mitochondrial matrix of the distal tubular epithelium in
the Ge02 group. Although systemic toxicities were reduced after Ge02
was discontinued at week 24, renal tubulointerstitial fibrosis became
prominent even at week 40 (16 weeks after discontinuation). A Ge Ka
X-ray spectrum was clearly demonstrated in the mitochondrial matrix
of the distal tubular epithelium in the Ge02 group with the help of
electron probe X-ray microanalysis. On the other hand, neither toxic
effects nor renal histological abnormalities were manifested in either the
Ge-132 or the control group. The renal tissue content of germanium was
high at weeks 24 and 40 in the Ge02 group. From these results, it is
concluded that Ge02 causes characteristic nephropathy while Ge-132
does not. In addition, it appears that residual Ge02 remains for a
considerably long time even after the cessation of Ge02 intake.
Germanium (Ge; atomic number 32, atomic weight 72.59)
belongs to the IV group of the periodic system and is a
semiconductor that has been used mainly in the industrial field.
It is an ubiquitous biomaterial, and is contained in almost all
foods even if only in minute amounts [11. Some biological
activities such as erythropoietic action [2, 3] and antimicrobial
activity [4] have been shown in either germanium dioxide
(Ge02) or organogermanium derivatives. Carboxyethylgerma-
nium sesquioxide (Ge-l32) was synthesized by Asai et al and
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has been well characterized in Japan [5]. This compound has
also been reported to have an anti-tumor effect [6, 71, an
inhibitory effect on amyloidosis [81, as well as possessing
immunomodulatjve activity [9—11]. On the other hand, toxici-
ties of some germanium compounds have been reported in spite
of their medical utility [12—16]. However, there have been no
reports describing toxicity of oral germanium compounds [17]
except for Rosenfeld and Wallace's study [15].
In Japan, some people take Ge-containiig compounds orally
as a kind of elixir. We have experienced several cases of
patients who took Ge-containing compounds and later went into
progressive renal failure. These cases showed an uncommon
clinical course and characteristic renal histology [18]. In partic-
ular, long-lasting renal dysfunction even after the cessation of
Ge compound ingestion has been characteristic. Since these Ge
compounds contained Ge02, we reported the renal lesions as
being Ge02-induced nephropathy [19]. Recently, other similar
cases have been reported in Japan [20—23]. Germanium has also
recently gained in popularity in Germany, USA, and the United
Kingdom, among other countries. According to Lancet [24], the
popularity of germanium, which began in Japan in the 1970s,
took off in Britain in 1987 with a claim (clearly directed at AIDS
patients) that it would "rebuild your compromised immune
system", and there are now 15 different brands of germanium
compounds on the United Kingdom market.
Venugopal and Luckey [17] reported that organic derivatives
of the metals of Group IV are more toxic than are the inorganic
salts. However, we experienced two patients who developed
renal failure due to the ingestion of Ge02 after the cessation of
Ge-l32 or organic Ge compound (unpublished data). Further-
more, subacute nephrotoxicity was not induced by Ge-132 but
by Ge02 in our preliminary animal study [19].
In the present study, to examine the chronic nephrotoxicity
of Ge compounds, we observed both renal function and histol-
ogy for 16 weeks by administering two kinds of Ge compounds,
Ge02 and Ge-132, for 24 weeks. We tried to detect the
localization of either Ge . Ka or Ge - La X-ray spectrum in the
tubular epithelial cell organellae under X-ray microanalysis.
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Methods
Experimental design
Study I: Chronic administration and withdrawal study. Using
Wistar female rats (Kyushu University Animal Center, Fuku-
oka, Japan), 140 to 190 g of body weight, three experimental
groups were prepared: one group was treated daily with 75
mg/kg body wt of Ge02 (molecular weight 104.59, Sumitomo
Metal Mining Co., Tokyo, Japan) (Ge02 group, N = 20 rats);
another group was given 120 mg/kg of Ge-132
[(GeCH2CH2COOH)203, molecular weight 339.32, ASAI Ger-
manium Institute, Tokyo, Japan] (Ge-132 group, N = 19); and a
control group was administered no Ge compounds (N 16).
The dose of the two kinds of Ge compounds contained an equal
amount of Ge. Each Ge compound was mixed into the pow-
dered rat chow (CE-2, Clea Japan Inc., Tokyo, Japan). The
constant dose of each Ge compound was administered in spite
of the alteration of diet intake and body weight. To maintain an
equal caloric and protein intake, all groups were pair-fed with
the group which had minimal ingestion. All groups had free
access to tap water. After week 24, Ge administration was
discontinued and a Ge-free diet was provided to all the groups.
To investigate both the tissue concentration of Ge and renal
histology, rats were sacrificed at weeks 24, 26 and 40. The latter
two periods were 2 and 16 weeks after the cessation of Ge. To
determine the kidney concentration prior to a major fall in
glomerular filtration rate, six rats from each group were sacri-
ficed at week 6. Body weight, hematocrit, BUN, serum creat-
mine, and 24-hour urinary protein excretion were examined
every four weeks. Systolic blood pressure was measured every
eight weeks. The serum total protein, albumin, cholesterol,
phosphate, GOT and GPT, and urinalysis were examined at
weeks 24 and 40. Creatinine clearance (Car), fractional excre-
tion of sodium (FENa), urinary N-acetyl-beta-D-glucosamini-
dase (NAG) concentration and urinary Ge concentration were
examined at week 24.
Study II: High dose study in Ge02-treated rats for electron
energy dispersive X-ray microanalysis (EDX). Five Wistar
female rats (150 to 200 g body wt) were treated with 450 mg/kg
body wt/day of Ge02 for two weeks and sacrificed for light
microscopic, electron microscopic study, and EDX analysis.
The sections were observed and elementally analyzed with an
electron probe X-ray microanalyzer.
Analytical methods
Hematocrit was determined by the microhematocrit method
[25], serum and urinary creatinine by the Jaffe reaction [26],
BUN by the reduced nicotinamide adenine dinucleotide-cou-
pled reaction [271, serum total protein by the biuret reaction
[28], albumin by the use of bromcresol green [29], cholesterol
by an enzymatic method [30], and phosphate by the Fiske and
Sabbarow's method [311. GOT and GPT were determined by
the method of Karmen, Wrobewski and Ladue [32], serum and
urinary sodium by use of flame photometer, 24-hour urinary
protein excretion by the sulfosalicylic acid method [33], NAG
by the MCP-NAG method [34], and urinalysis by N-multistix
(Ames-Sankyo Co., Tokyo, Japan). Systolic blood pressure
was measured in the conscious state by the tail cuff method. Ge
concentration of the tissue was determined by the flameless
atomic absorption method (AA-670, Shimadzu, Kyoto, Japan),
and urinary Ge concentration by a polarized Zeeman atomic
absorption spectrometer (Z-6l00, Hitachi Co., Tokyo, Japan).
These determinations were performed by technicians who had
no prior knowledge of the experimental groups.
Morphological analysis
The kidney and heart were fixed in 6% neutral buffered
formalin and stained with hematoxylin and eosin (H&E) and
periodic acid-Schiff reagent (PAS). The former was also stained
with SUDAN III and the latter with Heidenhain's azocarmine
(AZAN).
Histological evaluation was made independently by two
investigators without prior knowledge of the experimental
groups. A semiquantitative score was used to evaluate the
degree of tubular changes according to the method of Risdon,
Sloper and de Wardener [35]. The tubular change was ex-
pressed by the number of microscopic fields where unequivocal
degeneration was found, observing a hundred consecutive
microscopic fields in the cortex of each specimen with the aid of
a 40x objective.
For the immunohistological studies, a 4 tm thick kidney
section was exposed to Iluorescein isothiocyanate conjugated
anti-rat-IgG, IgA, 1gM, or C3 goat serum (Cappel Laboratories,
Cochranville, Pennsylvania, USA).
For the electron microscopic studies, specimens were fixed in
3% glutaraldehyde buffered to pH 7.2 with 0.1 M cacodylate
buffer at 4°C, postfixed in 1% osmium tetroxide, dehydrated
and embedded in Spurr's low viscosity resin. Ultrathin sections
were double stained with uranyl acetate and lead citrate at 50°C
using the microwave system [36], and observed under the
JEM- 1 200EX transmission electron microscope (Nihon-Denshi
Co., Tokyo, Japan). Unstained ultrathin sections were analyzed
with an EDX system (EDAX-PV-9800, Japan Philips, Ltd.,
Tokyo, Japan) at 40 to 60 kV accelerating voltage for 200
seconds. The obtained X-ray spectra were analyzed with a
computer EDX system.
Statistical analysis
Data are expressed as mean SD. Statistical difference was
calculated using the one way analysis of variance among groups
and the unpaired i-test with Bonferroni's method, except where
otherwise noted. A level of 0.05 was regarded as significant.
Results
Study I: Chronic and withdrawal study
Body weight, systolic blood pressure and hematocri. The
rats of the GeO2 group developed a marked body weight loss
after week 12 of treatment, and they became inactive and
listless after week 20. One rat died from azotemia at week 23.
As shown in Figure 1A, the body weight was significantly lower
in the Ge02 group than in either the Ge-132 or the control group
after week 12 (P < 0.05), although there was no difference
between the latter two groups throughout the experiment ex-
cept week 24. At week 24 the body weight was 108 7 g, 184
12 and 170 9 in the GeO2, Ge-132 and control groups,
respectively. Following the cessation of Ge02 at week 24, the
reduced body weight increased markedly but did not reach the
level of other two groups by week 40.
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Systolic blood pressure did not differ among the groups
except week 24, when that in the Ge02 group (109 4 mm Hg)
was significantly higher than that in the Ge-132 group (101 6;
P < 0.01). However, there was no significant difference be-
tween the Ge02 or the Ge-132 group and the control group (105
5).
Hematocrit in the Ge02 group was 44.3 1.6%, which was
significantly lower than that of 46.4 1.1% in the control group
at week 12 (P < 0.01) as shown in Figure lB. Even after Ge02
was discontinued, hematocrit in this group remained signifi-
cantly lowered, compared with that in the control group at
weeks 32 and 36 (P <0.05). In contrast, there was no significant
difference in hematocrit between the Ge-132 and control groups
throughout the experiment.
Blood and urine chemistries, BUN in the Ge-132 group
increased at weeks 4 and 12, following by a significant decrease
at week 20 compared with the control group (P < 0.05, Fig. IC).
In contrast, BUN in the Ge02 group increased greatly at week
28 and slightly but significantly at week 40 (37 11 and 23 1
mg/dl, respectively, P < 0.05). BUN in the control group
remained unchanged during the 40 weeks observation.
Serum creatinine was significantly lower in the Ge02 group
than in the Ge-132 or control group at weeks 16, 20, 28, and 32
(P < 0.05; Fig. ID). BUN/serum creatinine ratio was signifi-
cantly higher in the Ge02 group than in the Ge-l32 or control
group from week 16 to 28 and at week 40 (P < 0.05).
Ccr was significantly lower in the Ge02 group (123 51
ml/day/g kidney wt) than in the Ge-l32 group (452 151) or
control (436 243) at week 24 (P < 0.05). Both FENa and
NAG/Uprotein levels were two to three times higher in the Ge02
group (1.3 0.4% and 39 14 mU/mg) than in the Ge-132
group (0.3 0.1 and 9 2) or control (0.5 0.2 and 18 11)
at week 24 (P < 0.05).
Urinary protein excretion was slight and did not differ among
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Fig. 1. Time course of body weight, hematocrit, blood urea nitrogen, and serum creatinine. A Body weight and amount of food taken (g). B
Hematocrit (%). C Blood urea nitrogen (mg/dl). D Serum creatinine (mg/dI). Data are expressed as the mean SEM. Symbols are Group: Ge02
(•), Ge-132 (fl), and Control (0). *p < 0.05, < 0.01, ***<0.00! (vs. Control group), P < 0.05, 'P < 0.01, < 0.001 (vs. Ge-132 group).
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Table 1. Serum cholesterol (Chol), GOT, GPT, and phosphate (P)
Group
No. of
rats
Chol
mg/dl
GOT GPT
mg/dlU/liter
Week 24
Ge02 13 103 24"" 419 312" 42 18 5.6 2.0"
Control 10 73 12 83 32 19 4 4.2 1.0
Ge-l32 13 76 9 79 17 21 6 3.8 0.5
Week 40
GeO2 4 67 4 73 11 22 2 4.1
Control 5 55 9 86 20 19 4 3.1 0.6
Ge-132 4 59 4 76 13 20 2 2.9 0.2
Abbreviations are: GeO2, rats were administered with 75 mg/kg body wt/day of GeO2; Ge-132, rats were administered with 120 mg/kg body
wt/day of Ge-132; Control, rats were bred with a Ge free diet. Ge compounds were discontinued at week 24. Data are expressed as the mean
SD.
a P < 0.001, '' P < 0.05 (vs. Control group)
P <0.001," P <0.01, "P <0.05 (vs. Ge-l32 group)
the mean SD.
the three groups. Neither hematuria nor glucosuria was de-
tected in any of the rats from the three groups throughout the
experiment.
Serum cholesterol, GOT, GPT, and phosphate were all
significantly more elevated in the Ge02 group than in either the
Ge-132 or control group at week 24 (P < 0.01). At week 40, or
16 weeks after treatment discontinued, the serum phosphate
remained high in the Ge02 group (P < 0.05) but other variables
had returned to the control levels (Table 1). In contrast, neither
serum total protein nor the albumin levels differed among the
groups.
Organ weight. Kidney weight increased in the GeO2 group at
week 24, being significantly higher than in the Ge-132 or control
group (P < 0.05). In contrast, liver weight significantly de-
creased in the Ge02 group but increased in the Ge-132 group at
week 24 (P < 0.05). At week 40, liver weight decreased in the
Ge-132 group, compared with the control group (P < 0.05;
Table 2).
Germanium concentration in tissue and urine. At week 6,
kidney concentration of Ge was higher in the Ge02 group (11.2
2.7 Lg/g wet wt) compared to the Ge-132 group (0.8 0.2; P
< 0.001, Student's t-test) or control (not detected).
As shown in Table 3, Ge concentrations in the kidney, heart,
liver, muscle, and hair were higher in the GeO2 group than in
the other groups at week 24. Tissue Ge concentrations in these
organs were reduced but remained higher in the GeO2 group
than in the Ge-132 or control group at week 26 or two weeks
after the discontinuation of Ge compounds. Particularly in the
kidney and hair, tissue Ge concentration was still significantly
higher in the GeO2 group than in the Ge- 132 or control group
even 16 weeks after Ge was discontinued (at week 40; P < 0.05
for kidney or hair, respectively).
The urinary excretion of Ge at week 24 was significantly
higher in the GeO2 (768.9 376.9 pg/day) and Ge-l32 (539.5
228.3) groups than in the control group (8.1 8.7; P <0.001).
However, there was no difference between the former two
groups.
Morphological findings. At week 24, vacuolar degeneration
was observed in the tubular epithelium in the GeO2 group by
light microscopic examination. Granular particles stained in
purple with PAS and large vacuoles stained with SUDAN III
were predominantly detected in the epithelium of dilatated
distal tubules and collecting tubules. Tubular atrophy, epithelial
cell necrosis nd desquamation were partly evident in the GeO2
group. Although proximal tubular injury also occurred such as
vacuolar alteration of epithelial cells, the above mentioned
histological changes localized mainly in distal segment of the
tubules. A slightly sclerotic change was also partly observed in
the Ge02 group, although the glomeruli were mostly intact (Fig.
2A, B). By electron microscopic observation, the number of
mitochondria increased and electron-dense granules were char-
acteristically detected in the swollen mitochondria in distal and
collecting tubule epithelium, in which both the cristae and
matrix were often seen to have disappeared in the GeO2 group
(Fig. 2C). The same granules were also detected in the lyso-
somes. Sulfur, zinc, and a trace of Ge were found in these
Table 2. Organ weight
Group
No. of
rats
Kidney Heart Liver
g
Week 24
Ge02
Control
Ge-l32
Week 40
GeO2
Control
Ge-132
6
5
5
4
5
4
1.45 0.14""
1.09 0.08
1.24 0.10
1.15 0.02
1.22 0.04
1.13 0.09
0.60 0.06
0.56 0.04
0.59 0.04
0.60 0.05
0.64 0.04
0.60 0.04
3.55 0.14""
4.45 0.68
5.44 0.42"
4.43 0.25
5.04 0.70
3.75 025b
Ge compounds were discontinued at week 24. Data are expressed as
aP < 0.001, b p < 0.01, "P < 0.05 (vs. Control group)d P < 0.001, "P < 0.05 (vs. Ge-132 group)
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Table 3. Tissue concentration of germanium (Ge)
Group
No. of
rats
Kidney Heart Liver Muscle Hair
rg/g wet wt
Week 24
Ge02 6 34.0 24.6e 7,9 3,7C 27.7 16.6 8.7 4.3 171.2 96,6 (13)
Control 5 0.4 0.4 ND ND ND 2.8 1.5 (10)
Ge-132 5 0.8 0.2 0.3 0.2 ND ND 7.2 3.6 (13)
Week 26
Ge02 4 2.3 0.6 0.5 0.6 1.2 0.2 0.8 0.3 107.8 18.2 (8)a
Control 5 — — — — 2.5 0.9
Ge-132 4 1.6 1.7 0.2 0.1 0.6 0.5 ND 5.2 1.7 (8)
Week 40
Ge02 4 1.1 01b.e ND 0.3 0.2 ND 14.2 7,9c,f
Control 5 0.2 0.1 ND ND ND 4.7 1.3
Ge-l32 4 0.4 0.4 0.2 0.3 0.3 0.3 ND 3.8 2.9
Tissue concentration of Ge in Ge02 or Ge-132 group at week 26 was compared with that in the control group at week 24. The differences between
Ge02 and Ge-132 groups are calculated using Student's t-test in the heart at weeks 24 and 26, or in the liver at weeks 26 and 40. Ge compounds
were discontinued at week 24. ND; not detected. The number of rats is in parentheses. Data are expressed as the mean SD.
a P < 0.001, b p < 0.01, P < 0.05 (vs. Control group), d P < 0.001, C P < 0.01, P < 0.05 (vs. Ge-132 group).
inclusions by EDX analysis. These changes were not evident in
the Ge-132 and control groups. No deposition of immunoglob-
ulin or complement such as IgG, IgA, 1gM or C3 was observed
in any of the rats among the groups. No significant pathological
changes were observed in the myocardial cells in any group.
At week 40 severe tubular atrophy, interstitial fibrosis and
cellular infiltration manifested in the Ge02 group, although
PAS-positive granules in distal tubules almost disappeared (Fig.
2D). These changes were not detected in either the Ge-132 or
the control group. As depicted in Table 4, tubular changes were
more marked in the Ge02 group than those in the Ge-l32 or
control group (P < 0.001).
Study II: High dose study of Ge02 for EDX analysis
All rats became cachectic after a one week administration of
450 mg/kg/day Ge02. Vacuolation and purple granules were
also observed in the renal tubular epithelium. The Ge . K line
was clearly detected from the electron-opaque inclusion body
of swollen mitochondrion in the distal tubular epithelium in the
unstained ultrathin sections by EDX analysis with other ele-
ments, which included P. K (phosphorus), S . K (sulfur),
Cl. K (chloride), Ca. K (calcium), Fe• K (iron) and Zn. K
(zinc). A very large amount of iron and sulfur seemed to be
included in the tissue, as shown in Figure 3 and Table 5.
Discussion
We have previously reported four patients who developed
characteristic renal deterioration after the long-term ingestion
of the Ge-containing compounds, as Ge-induced nephropathy
[18]. Using the X-ray diffraction method, we observed Ge02 in
the Ge compounds which these patients had ingested [19]. The
present study confirmed that Ge02 induced chronic nephrotox-
icity, while an organic germanium compound Ge-l32 did not
have any toxic effects. Furthermore, liver dysfunction as well
as systemic toxicities (weight loss, anemia, and central nervous
disorders) developed only in the Ge02 group of the present vivo
study, and Ge02 proved to be more cytotoxic than Ge-132 in
the macrophages of the in vitro study (unpublished data). These
results indicate the clear difference in toxicity among the
different Ge-compounds. Rosenfeld and Wallace [15] reported
that germanium itself is pharmacologically inert, and toxicity of
any compound seems due to the toxic effects of the nongerma-
nium inorganic, aliphatic, or aromatic portion of the molecules.
Although Venugopal and Luckey [17] reported that organic Ge
compounds are more toxic than inorganic compounds, the
present study revealed evidence to the opposite. Toxicological
and pharmacokinetic studies previously revealed that Ge- 132
has an extremely low toxicity [9, 37, 38]. Likewise, our present
study demonstrated that Ge-132 had an extremely low toxicity.
There have been some reports [9—11] describing that Ge-l32
activates macrophage, possesses anti-oxidant activity [39], and
has a protective effect on the warm ischemic injury in renal
transplantation [40].
The precise mechanism of Ge02-induced renal toxicity is still
unclear. In the present study, the creatinine clearance signifi-
cantly decreased in the Ge02 group compared to the Ge-132 and
the control groups. The decrease in body weight and the
elevation of the BUN/serum creatinine ratio suggest that the
renal functional deterioration might be induced by the reduction
in ECF associated with gastro-intestinal toxicity of Ge02 [41].
However, pair-feeding was performed to maintain the same
amount of food intake among the groups, and a decrease in
FENa was not observed in the Ge02 group. Furthermore, the
blood pressure in the Ge02 group was higher than that in the
other groups at week 24. These results suggest that the weight
loss and the elevation of BUN/serum creatinine ratio is due to
catabolism induced by the systemic toxicity rather than dehy-
dration. Serum creatinine did not increase regardless of the
Fig. 2. Renal histology in Ge02 group. A, B Vacuolar degeneration is observed in the tubular epithelium, and tubular atrophy is also partly
observed. Purple dense deposits, large vacuoles, and dilatation are detected in the distal segments. Glomeruli are slightly sclerotic but mostly
intact. (week 24, PAS-stain, A. x220, B. x320. C Electron-dense inclusions exist in the rounded mitochondna of distal tubular epithelium. (week
24, x45,000). ii Tubular atrophy, interstitial fibrosis and cell infiltration are manifested. Glomeruli are mostly intact. (week 40, PAS-stain, x220)
-fl e.
-I'
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Table 4. Renal tubular degeneration (%)
Group Week 24 Week 26 Week 40
Ge02 95 9 (6)a.h 85 6 (4)a.b 77 9 (4)'
Control 1±1(5) — 2±1(5)
Ge-132 3±1(5) 4±2(4) 2±2(4)
Renal tubular degeneration in Ge02 or Ge-l32 group at week 26 is
compared with that in the control group at week 24. Ge compounds
were discontinued at week 24. The number of rats is in parentheses.
Data are expressed as the means sD.
a P < 0.001 (vs. Control group)
Ii P C 0.001 (vs. Ge-132 group)
Table 5. Amounts of elements in the electron opaque inclusion body
CPS/BKGD WT%Element CPS BKGD
P K 3.42 4.46 0.77 7.21
S K 9.65 4.33 2.23 19.07
Cl . K 9.16 4.t5 2.21 17.92
Ca K 2.05 3.41 0.60 3.94
Fe• K 17.30 3.28 5.27 40.74
Zn . K 1.50 3.29 0.46 4.40
Ge . K 2.03 2.60 0.78 6.72
Abbreviations are: CPS, X-ray pulse counts per second; BKGD,
background; WT%, atomic weight ratios %. Data are calculated from
Figure 3.
Fig. 3. X-ray energy spectrum obtained from the
electron-opaque inclusion body in the unstained
450 mg/kg Ge02 administered rat renal distal
tubular epithelial cell. The X-ray energy peaks of
P. K, S . K, Cl. K, Ca K, Fe . K, Zn. K, and
Ge . K were clearly demonstrated. A remarkable
amount of S K was noted with other elements.
-.
* Nickel grid was used and the currsor is localized
at the location of Ge . K X-ray energy peak, 9.88
keV. (60 kV, 200 seconds, calculated with
"Super Quant" program of EDAX-PV-9800
analyzing system).
reduction in creatinine clearance. The discrepancy between
serum creatinine and creatinine clearance may be explained by
the reduction in lean body mass.
At week 6, prior to a major fall in GFR, kidney concentration
of Ge was higher in the Ge02 group than in the Ge-l32 or
control group, and Ge was also detected in the electron-dense
granules in the present study. Therefore, the marked accumu-
lation of the compound in the renal tissue seems to play an
important role. In a previous death case, in which the patient
had taken a long-term Ge02 preparation, Ge accumulation into
several organs including the kidney was observed [41]. Since
neither immunoglobulin deposition nor significant interstitial
cell infiltration was observed in the kidney at week 24 of Ge02
treatment, the immunological mechanism does not seem to
work in these renal changes. Tubular histological damage such
as vacuolar degeneration, atrophy, necrosis and desquamation,
and biochemical abnormalities such as the increase of FENa and
NAG excretion, suggest that the direct cytotoxic effect of Ge02
on the renal tubular epithelium contributes to renal damage in
the Ge02-treated rats.
Mitochondrion is the major source for the production of
cellular high energy phosphate, ATP. In addition, enzymes of
the Krebs cycle, such as oxidative phosphorylation and respi-
ratory chain, are found to be largely confined to the mitochon-
drial fraction [42]. The ATP content and Na-K-ATPase activity
in renal cortex of rats were reduced by cadmium administra-
tion, whereby the amount of cadmium increased in the mito-
chondrial fraction and mitochondria became swollen [43]. Cre-
mer and Aldridge [16] reported that tri-n-butyl-germanium had
some inhibitory effects on the respiration and oxidative phos-
phorylation processes of rat liver mitochondria, and a high
concentration of this compound causes gross swelling of the
mitochondria. Since cell degeneration and gross mitochondria
swelling were evident in the present study, mitochondrial
dysfunction might result in compromized cell's energy supply
and structural disintegration in the Ge02-induced nephrotoxic-
ity.
Metallothionein, which contains sulfur, zinc, iron, and cop-
per, is well known as a binding protein of cadmium [44, 45]. In
the present study, these three elements were detected in the
electron-opaque inclusion, and their distribution ratios in both
CPS and WT% were high for sulfur, suggesting a possible role
of metallothionein in GeO,-induced nephrotoxicity. Further
investigations may be needed to clarify the mechanism.
The histological damage in the Ge02-treated rats at week 24
is mild compared with acute renal failure induced by heavy
metals. In this model, vacuolar degeneration is prominent, but
the general outline of the proximal tubule cells and nuclei are
preserved. These histological characteristics were similarly
CaKa
GeKa
2.00 4.00 6.00 8.00
38 CNT 9.88 KEV 10 eV/ch
10.00
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found in our human study [19], in which patients with deterio-
rated renal function had a well-preserved histology. The clinical
feature of this nephropathy was that of subacute renal failure
rather than that of acute renal failure. The renal dysfunction
persisted for a long time even after Ge02 administration was
discontinued. However, proteinuria or hematuria was not evi-
dent, and other specific clinical symptoms or signs were lacking
[19]. In the present study, neither interstitial fibrosis nor cellular
infiltration was demonstrated at week 24 in the Ge02 group, but
these changes became manifest at week 40 or 16 weeks after
discontinuation, when Ge concentration in the kidney remained
high. These findings suggest that Ge02-induced nephrotoxicity
results in an irreversible chronic interstitial nephritis and lasts
for a long-term period even after removing Ge02 from food.
This nephropathy may be in part related to the long-lasting
Ge02 accumulation in renal tissue.
In summary, we demonstrated the severe nephrotoxicity
induced by Ge02. Chronic Ge02-induced nephropathy is char-
acterized by progressive and long-lasting renal damages with a
lack of any abnormal urinalysis. This nephropathy, which
seems to be different from the previously reported renal dis-
eases, might be a new and independent disease entity.
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